Survivin is a negative prognostic factor in malignant pleural effusion

Survivin is a negative prognostic factor in malignant pleural effusion INTRODUCTIONA malignant pleural effusion (MPE) is defined by an increase in the volume of pleural fluid accompanied by the presence of malignant cells. MPE may develop because of a primary pleural malignancy, for example mesothelioma, but more commonly occurs following metastatic cancer. The number of new patients diagnosed with MPE diagnosed in Europe each year is over 100 000, with lung cancer being the most common underlying aetiology (accounting for approximately one‐third of all cases). Other secondary malignancies that may cause MPE include breast cancer, lymphoma, ovarian cancer, colon cancer and other solid tumours. Because pleural involvement generally reflects the presence of advanced‐stage tumours, the treatment for MPE is aimed to prevent recurrences by obliterating the pleural cavity; this can be achieved by introducing a sclerosing agent into the pleural space (pleurodesis). It is expected that approximately 60% of patients with MPE will require pleurodesis to prevent fluid reaccumulation, especially in the presence of large and/or recurrent pleural effusions. Owing to its good safety profile, talc remains the most commonly used sclerosing agent for recurrent MPE. Specifically, calibrated talc has gained popularity for chemical pleurodesis. The mechanisms of talc‐induced artificial obliteration of the pleural space include the induction of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Investigation Wiley

Loading next page...
 
/lp/wiley/survivin-is-a-negative-prognostic-factor-in-malignant-pleural-effusion-m0Wal4AMFE
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd
ISSN
0014-2972
eISSN
1365-2362
D.O.I.
10.1111/eci.12895
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONA malignant pleural effusion (MPE) is defined by an increase in the volume of pleural fluid accompanied by the presence of malignant cells. MPE may develop because of a primary pleural malignancy, for example mesothelioma, but more commonly occurs following metastatic cancer. The number of new patients diagnosed with MPE diagnosed in Europe each year is over 100 000, with lung cancer being the most common underlying aetiology (accounting for approximately one‐third of all cases). Other secondary malignancies that may cause MPE include breast cancer, lymphoma, ovarian cancer, colon cancer and other solid tumours. Because pleural involvement generally reflects the presence of advanced‐stage tumours, the treatment for MPE is aimed to prevent recurrences by obliterating the pleural cavity; this can be achieved by introducing a sclerosing agent into the pleural space (pleurodesis). It is expected that approximately 60% of patients with MPE will require pleurodesis to prevent fluid reaccumulation, especially in the presence of large and/or recurrent pleural effusions. Owing to its good safety profile, talc remains the most commonly used sclerosing agent for recurrent MPE. Specifically, calibrated talc has gained popularity for chemical pleurodesis. The mechanisms of talc‐induced artificial obliteration of the pleural space include the induction of

Journal

European Journal of Clinical InvestigationWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial